Michael T. Beste
0000-0002-1343-0005
Publication & Citation Trends
Publications
0 total
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy OA
Cited by 9
Semantic Scholar
Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial.
Cited by 9
Semantic Scholar
Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial OA
Cited by 43
Semantic Scholar
Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background OA
Cited by 9
Semantic Scholar
P1339: IMPACT OF CLONAL HEMATOPOIESIS AND CANAKINUMAB ON NON-HEMATOLOGICAL MALIGNANCY: ANALYSIS OF THE CANTOS RANDOMIZED CLINICAL TRIAL OA
Cited by 0
Semantic Scholar
Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study
Cited by 0
Semantic Scholar
Endometrial cytokines in patients with and without endometriosis evaluated for infertility. OA
Cited by 19
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(27)
Lung Cancer Treatments and Mutations
(17)
Hepatocellular Carcinoma Treatment and Prognosis
(14)
Pancreatic and Hepatic Oncology Research
(9)
Chronic Lymphocytic Leukemia Research
(9)
Affiliations
Novartis (Switzerland)
American Institutes for Research
Boston Biomedical Research Institute
In-Q-Tel
Novartis (China)